BORTEZOMIB | N021602 | TAKEDA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2020-05-20 | Terminated 2020-08-20 | — | |
| D. Del. | 2019-12-10 | Terminated 2020-03-25 | — | |
| D. Del. | 2019-03-06 | Terminated 2020-06-10 | — | |
| D. Del. | 2017-04-13 | Terminated 2019-09-12 | — | |
| D. Del. | 2017-04-13 | Terminated 2019-09-18 | — | |
Millennium Pharmaceuticals Inc. v. Wockhardt Bio AG et al 2 patentsANDA 208497bortezomib | D. Del. | 2016-01-22 | Terminated 2018-04-06 | — |
| M.D. Tenn. | 2014-07-28 | Terminated 2014-12-09 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Actavis Inc. - Citizen Petition FDA-2012-P-0272 · 3 docket documents Actavis Inc filed this citizen petition on March 14, 2012 pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, requesting that the FDA declare Bortezomib for Injection at 1 mg and 2.5 mg strengths suitable for submission in an abbreviated new drug application, representing a | Other | 2012-03-26 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.